6457-48-3

Usage

Uses

1-(4-Piperidinyl)ethanol is used to prepare selective biaryl ethers as PDE10A inhibitors.

InChI:InChI=1/C7H15NO/c1-6(9)7-2-4-8-5-3-7/h6-9H,2-5H2,1H3

Upstream product

• 23389-75-5 rac-1-(pyridin-4-yl)ethanol 
• 206989-61-9 4-acetyl-1-(t-butoxycarbonyl)piperidine 
• 183170-69-6 1-tert-Butyloxycarbonyl-4-hydroxyethyl-piperidine 
• 1122-54-9 methyl (4-pyridyl) ketone 

Downstream Products

• 194151-34-3 (+/-)-1-{1-[4-(1-{piperidin-4-yl}ethoxy)-2-methoxybenzoyl]-piperidin-4-yl}-4H-3,1-benzoxazin-2(1H)-one 
• 183170-69-6 1-tert-Butyloxycarbonyl-4-hydroxyethyl-piperidine 
• 1314528-14-7 C₂₄H₃₀Cl₂N₄O 
• 1314530-71-6 N-(4-bromomethyl-5'-chloro-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-yl)-3-chloro-benzamide 
• 1314530-70-5 3-chloro-N-[5'-chloro-4-(1-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-yl]-benzamide 
• 1032825-55-0 tert-butyl 4-(1-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate 
• 1422394-73-7 2-(2,6-difluorophenyl)-N-(5-(4-(1-hydroxyethyl)piperidin-1-yl)isothiazol-4-yl)thiazole-4-carboxamide 
• 1227066-17-2 1-(1-(3-(4-(benzo[d]thiazol-2-ylamino)phenoxy)pyrazin-2-yl)piperidin-4-yl)ethanol 
• 86543-29-5 N-(2-Cyano-4,5-dimethoxy-phenyl)-4-(1-hydroxy-ethyl)-piperidine-1-carboximidothioic acid methyl ester 
• 86543-22-8 4-(1-Hydroxy-ethyl)-piperidine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 

Relevant academic research and scientific papers

CXCR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1 to R3, A, B, X, and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

ANDROGEN RECEPTOR MODULATING COMPOUNDS

Compounds of formula (I) wherein R1 to R16, A. B and E are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).